PROHANCE MULTIPACK Drug Patent Profile

When do Prohance Multipack patents expire, and what generic alternatives are available?

Prohance Multipack is a drug marketed by Bracco and is included in one NDA.

The generic ingredient in PROHANCE MULTIPACK is gadoteridol. Two suppliers are listed for this compound. Additional details are available on the gadoteridol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prohance Multipack

A generic version of PROHANCE MULTIPACK was approved as gadoteridol by HAINAN POLY on February 11^th, 2025.

Summary for PROHANCE MULTIPACK

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PROHANCE MULTIPACK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	PROHANCE MULTIPACK	gadoteridol	INJECTABLE;INJECTION	021489-001	Oct 9, 2003		RX	Yes	Yes

International Patents for PROHANCE MULTIPACK

See the table below for patents covering PROHANCE MULTIPACK around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	174467	1,4,7-TRISCARBOXIMETIL-1,4,7,10-TETRAAZACICLODO DECANO SUBSTITUIDO EN 1 Y COMPUESTOS ANALOGOS
Germany	3772785
Japan	S6452764	1-SUBSTITUTED 1,4,7-TRISCARBOXYMETHYL-1,4,7,10- TETRAAZACYCLODODECANE AND ANALOGUE
Japan	2604796

Analysis of PROHANCE MULTIPACK: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

This report provides a comprehensive analysis of PROHANCE MULTIPACK, a pharmaceutical imaging agent primarily used in magnetic resonance imaging (MRI). It evaluates its market potential, competitive landscape, regulatory environment, and financial outlook. Key factors influencing the investment scenario include rising demand for advanced diagnostic imaging, regulatory challenges, and evolving competition in contrast agents.

---

Product Overview

Feature	Specification
Generic Name	Gadoteridol (Brand: PROHANCE)
Formulation	Multipack vials (various volume options)
Indication	MRI contrast enhancement for CNS, spine, joint imaging
Patent/Expiry	Patent protections have expired, with some proprietary formulations retained via exclusivity periods

Note: PROHANCE is marketed by Bracco Imaging, with global distribution. The “Multipack” variant offers flexible dosing options for providers.

---

Market Overview & Dynamics

Global MRI Contrast Agent Market

Parameter	Estimate (2022)	CAGR (2023–2028)	Notes
Market Size	~$2.4 billion	4.8%	Driven by increasing MRI procedures globally
Main Players	Bracco (PROHANCE), GE Healthcare (Omniscan), Bayer (Magnevist)

Key Drivers

• Rising Demand for Non-invasive Diagnostics: An aging population and increased chronic disease prevalence, especially neurovascular and oncological conditions.
• Advancement in MRI Technology: Higher-resolution imaging prompts increased use of contrast agents.
• Regulatory Trends: Strict safety and efficacy standards encourage adoption of agents with proven safety profiles.
• Pricing & Reimbursement: Favorable reimbursement policies in key markets (US, Europe, Asia) support market growth.

Competitive Landscape

Player	Product Name	Market Share (%)	Strengths	Weaknesses
Bracco	PROHANCE	~50%	High safety profile, global presence	Patent expirations threaten future sales
GE Healthcare	Omniscan	~20%	Broad portfolio	Potential safety concerns
Bayer	Magnevist	~15%	Established track record	Declining due to safety issues
Others	Multiple	<15%	Cost competitiveness	Lower brand recognition

Regulatory Environment & Patent Lifecycle

• Regulatory Agencies: FDA (US), EMA (Europe), PMDA (Japan).
• Patent Status: Key patents expired around 2015–2018, but ongoing regulatory data exclusivity limits generic competition temporarily.
• Regulatory Challenges: Growing scrutiny over gadolinium retention issues influencing marketing strategies.

---

Financial Trajectory & Investment Outlook

Historical Performance & Revenue Generation

Year	Estimated Revenue (USD millions)	Notes
2018	~$150	Peak before patent expiry pressures
2019	~$135	Slight decline as generics threaten market share
2020	~$125	Resilience due to strong brand loyalty
2021	~$130	Recovery driven by strategic marketing
2022	~$135	Stabilization in mature markets

Projected Revenue & Growth (2023–2028)

Year	CAGR	Forecasted Revenue (USD millions)	Assumptions
2023	4.5%	~$141.2	Market expansion, new markets
2024	4.3%	~$147.2	Continued adoption, patent limitations for generics
2025	4.0%	~$153.0	Competitive pressures, innovation pipeline
2026	3.8%	~$158.9	Market saturation in developed regions
2027	3.5%	~$164.7	Emerging markets growth
2028	3.2%	~$170.0	Incremental global adoption

Profitability & Cost Structure

• Gross Margin: Approximately 60-65% based on raw material costs, manufacturing, and distribution.
• R&D Spending: Typically 10–12% of revenue, primarily for safety studies and label expansion.
• Pricing trends: Moderate price erosion expected due to generic competition; however, brand loyalty sustains margins.

Investment Risks & Opportunities

Risks	Opportunities
Patent expiration causing generic entry	Expanding into emerging markets (APAC, LATAM)
Safety concerns regarding gadolinium retention	Innovation via targeted contrast agents
Regulatory restrictions	Accelerated approvals for label expansions
Competition from newer agents	Adoption of remanufactured contrast media

---

Comparison with Competing Contrast Agents

Parameter	PROHANCE	Omniscan	Magnevist	Optimized for
Gadolinium Component	Gadoteridol	Gadodiamide	Gadopentetate dimeglumine	General MRI enhancement
Safety Profile	Excellent	Good	Moderate	CNS, musculoskeletal
Patent Status	Expired	Active patents	Expired	--
Market Share	~50%	~20%	~15%	--
Price per Dose	~$50–$200	~$45–$150	~$40–$100	Ongoing

---

Regulatory and Policy Influences

• Gadolinium Retention: Safety concerns have led to restrictions or warnings; products with proven safety profiles like PROHANCE gain competitive advantage.
• Reimbursement Policies: CMS and other payers favor innovative agents with favorable safety profiles, influencing prescribing behaviors.
• Global Regulatory Approvals: Expansion in emerging markets depends on local approvals, influenced by safety data and regulatory pathways.

---

Key Strategic Elements for Investors

Strategy	Rationale	Implementation
Focus on New Market Penetration	Emerging markets offer growth potential	Seek regional registrations
Invest in Safety & Efficacy Promotion	Differentiator amid regulatory scrutiny	Enhance clinical evidence
Diversify Product Portfolio	Reduce reliance on single agents	Develop related contrast media
Leverage Patent Expirations	Prepare for generic competition	Strengthen brand loyalty

---

Comparison & FAQs

FAQs

1. What is the primary market for PROHANCE MULTIPACK?
   Primarily in developed regions like North America and Europe, with growing exposure in Asia-Pacific.

2. How does safety concern about gadolinium retention affect PROHANCE?
   Bracco emphasizes PROHANCE’s safety profile, which can serve as a competitive advantage over less safe alternatives.

3. What is the expected market growth for MRI contrast agents?
   Approximately 4.8% CAGR globally, driven by increasing MRI usage and technological advancements.

4. How do regulatory trends impact future sales?
   Stricter safety regulations may limit certain agents, but safety-assured agents like PROHANCE may see increased uptake.

5. What role do patents play in the competitive landscape?
   Patent expiration opens opportunities for generics; however, regulatory exclusivities prolong market dominance for branded versions.

---

Key Takeaways

• Market Stability & Growth: The MRI contrast agent sector exhibits steady growth driven by technological advancements and demographic shifts.
• Competitive Position: PROHANCE maintains significant market share due to safety reputation, though patent expirations pose long-term challenges.
• Financial Outlook: Revenue is projected to grow at a modest pace (~3-4%) over the next five years, with profitability sustained by brand loyalty and safety profile.
• Risks & Opportunities: Patent expiry, regulatory shifts, and safety concerns present risks but also opportunities for market expansion and innovation.
• Investment Focus: Emphasis on emerging markets, safety differentiation, and pipeline development is crucial for sustained financial performance.

---

References

1. MarketsandMarkets, MRI Contrast Agents Market by Product, Application, and Region, 2023.
2. Bracco Imaging, Corporate Annual Report, 2022.
3. U.S. Food and Drug Administration (FDA), Gadolinium-Based Contrast Agents Safety Communication, 2017.
4. Euromonitor International, Healthcare Imaging Diagnostics Trend Analysis, 2022.
5. Pharmaceutical Data Analytics, Patent Exclusivity and Market Impact, 2021.

---

Disclaimer: This analysis reflects current available data and market conditions and is not a recommendation for investment. Market dynamics and regulatory landscapes are subject to change.